During the Targeted Therapies in Lung Cancer Patient Forum, many of our fantastic and loved attendees shared with us what they are grateful for. For our sixth video in this month of gratitude, Ann Broo shared what she is thankful for with GRACE.
During the Targeted Therapies in Lung Cancer Patient Forum, many of our fantastic and loved attendees shared with us what they are grateful for. For our fifth video in this month of gratitude, Rita Johnson shared her thoughts with GRACE.
During the Targeted Therapies in Lung Cancer Patient Forum, many of our fantastic and loved attendees shared with us what they are grateful for. In this fourth video we feature our friend Mara Greenberg.
During the Targeted Therapies in Lung Cancer Patient Forum, many of our fantastic and loved attendees shared with us what they are grateful for. For our third video in this month of gratitude, Don Fredal shared with GRACE.
In this fourteenth video from the Targeted Therapies in Lung Cancer Patient Forum, we present the sixth from the afternoon breakout survivorship sessions, Love, Sex and Cancer, with Dr. Helen Coons.
GRACE is excited to continue to build the faculty and agenda for the upcoming Targeted Therapies Patient Forum, September 16, 2017. See more information about our presenters in Speaker Highlights - today we introduce Sara Whitlock, RET + patient.
GRACE is excited to continue to build the faculty and agenda for the upcoming Targeted Therapies Patient Forum, September 16, 2017. See more information about our presenters in Speaker Highlights - today we introduce Nathan Pennell, MD, PhD.
GRACE is excited to continue to build the faculty and agenda for the upcoming Targeted Therapies Patient Forum, September 16, 2017. See more information about our presenters in Speaker Highlights - today we introduce James Stevenson, MD.
GRACE is excited to continue to build the faculty and agenda for the upcoming Targeted Therapies Patient Forum, September 16, 2017. See our growing list of topics and presenters!
Christine M. Walko, Pharm.D., discusses how advancements in technology have improved the quality, cost and turnaround time for assessing genetic mutations in tumor tissue, and how this has helped to translate precision medicine into standard clinical practice.
On Saturday, November 10, 2018, GRACE partnered with Swedish Cancer Institute to present a live and webcast discussion on Local Therapies for...
Hi All - I was approached by a WhatNext Group partnered with Rare Patient Voice, with the opportunity to participate in a study specifically for Non...
Drs. Leora Horn, Ben Solomon, & Jack West assess whether clinical factors such as being a never-smoker or having a driver mutation (EGFR, ALK, etc.) reliably predict minimal benefit from immunotherapy agents.
Dr. Eddie Garon, UCLA, reviews the controversial question of whether PD-L1 expression is a reliable enough biomarker to be used to select patients to receive or not receive immune checkpoint inhibitor therapy in lung cancer.
Drs. Leora Horn, Ben Solomon, & Jack West consider the factors that might lead us to favor testing for PD-L1 at initial workup of a patient with advanced NSCLC or after progression.
Immune checkpoint inhibitors are now becoming approved and commercially available for patients with previously treated advanced NSCLC. Dr. Eddie Garon, medical oncologist at UCLA, summarizes key data and explains their current role in treatment.
Drs. Ben Solomon, Leora Horn, & Jack West consider how valuable testing for PD-L1 expression is in clinical practice and whether it should be integrated in clinical decision making around immunotherapies.
Dr. Ben Levy discusses two trials that are trying to determine if immunotherapy can help lung cancer patients with earlier stage disease. Click here for information about the PACIFIC trial. The lung cancer vaccine trial will begin in early 2016.
Dr. Nathan Pennell discusses ALCHEMIST, an NCI-sponsored clinical trial looking at whether targeted post-op (adjuvant) therapy for patients with a driver mutation such as EGFR mutation or ALK rearrangement improves survival.
ROS1 lung cancer patient Lisa Goldman credits research with keeping her alive. November is Lung Cancer Awareness Month. What are you grateful for?
Drs. Leora Horn, Ben Solomon, & Jack West consider whether the data suggest that the better tested PD1 and PD-L1 inhibitors have differences in activity or tolerability or are essentially interchangeable.
MSKCC medical oncologist Dr. Greg Riely reviews the optimal first line treatment of patients with an EGFR mutation-positive advanced lung cancer.
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.